T1	Participants 652 707	two primary breast cancer cohorts (n = 144 and n = 564)
T2	Participants 1135 1178	ER+ (Estrogen Receptor α positive) subgroup
T3	Participants 1341 1384	ER- (Estrogen Receptor α negative) subgroup
